• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

IMIPRAMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • IMIPRAMINE chembl:CHEMBL11 Approved

    Alternate Names:

    PRAMINE
    IMIPRAMINE
    TOFRANIL
    NSC-169866
    ORG-2463
    TOFRANIL-PM
    JANIMINE
    PRESAMINE
    IMIPRAMINUM
    IMIPRAMIN
    ANTIDEPRIN
    IRMIN
    MELIPRAMINE
    N-(GAMMA-DIMETHYLAMINOPROPYL)IMINODIBENZYL
    3-(5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE
    10,11-DIHYDRO-N,N-DIMETHYL-5H-DIBENZ[B,F]AZEPINE-5-PROPANAMINE
    5-[3-(DIMETHYLAMINO)PROPYL]-10,11-DIHYDRO-5H-DIBENZ[B,F]AZEPINE
    N-(Γ-DIMETHYLAMINOPROPYL)IMINODIBENZYL
    IMIZINE
    chembl:CHEMBL11
    drugbank:00458
    rxcui:5691
    pubchem.compound:3696
    chemidplus:50-49-7

    Drug Info:

    FDA Approval Approved before 1982
    Drug Class small molecule
    Drug Indications Antidepressive Agents, Tricyclic
    Year of Approval approved before 1982
    Drug Class antidepressive agents, tricyclic
    (4 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Kantor et al., 2001, Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells., J. Pharmacol. Exp. Ther.
    Tatsumi et al., 1999, Pharmacological profile of neuroleptics at human monoamine transporters., Eur. J. Pharmacol.
    Anton et al., 2004, Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells., J Gene Med
    Dziedzicka-Wasylewska et al., 2006, Effect of antidepressant drugs in mice lacking the norepinephrine transporter., Neuropsychopharmacology
    Mitchell et al., 2006, The effects of norepinephrine transporter inactivation on locomotor activity in mice., Biol. Psychiatry
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Toll et al., 1998, Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications., NIDA Res. Monogr.
    Leboyer et al., 1999, Decreased serotonin transporter binding in unaffected relatives of manic depressive patients., Biol. Psychiatry
    Schloss et al., 1995, Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1., Biochemistry
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Barkan et al., 2004, Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes., Eur Neuropsychopharmacol
    Scholze et al., 2000, Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter., J. Pharmacol. Exp. Ther.
    Quintin et al., 2001, Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder., Biol. Psychiatry
    Goulet et al., 2001, Non-amines, drugs without an amine nitrogen, potently block serotonin transport: novel antidepressant candidates?, Synapse
    Yagasaki et al., 2006, Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release., J. Biol. Chem.
    Kitamura et al., 2002, Effects of imipramine and lithium on wet-dog shakes mediated by the 5-HT2A receptor in ACTH-treated rats., Pharmacol. Biochem. Behav.
  • IMIPRAMINE   MC2R

    Interaction Score: 1.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11900811


    Sources:
    NCI

  • IMIPRAMINE   SLC6A2

    Interaction Score: 1.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    11356924 10193665 14716684 16554743 16893531


    Sources:
    TdgClinicalTrial TEND

  • IMIPRAMINE   SLC6A4

    Interaction Score: 0.97

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10624553 7548008 9537821 15056483 10869387 11513817 11746710


    Sources:
    TdgClinicalTrial TEND

  • IMIPRAMINE   BDNF

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16522641


    Sources:
    NCI

  • IMIPRAMINE   DRD1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    9686407


    Sources:
    DTC

  • IMIPRAMINE   CYP1A2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • IMIPRAMINE   CYP2D6

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC FDA

  • IMIPRAMINE   CYP2C9

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • IMIPRAMINE   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 9187528


    Sources:
    DTC PharmGKB

  • IMIPRAMINE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • IMIPRAMINE   EHMT2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: IMIPRAMINE

    • Version: 01-August-2011

    Alternate Names:
    IMIPRAMINE Primary Drug Name

    Drug Info:
    Drug Class antidepressive agents, tricyclic
    Year of Approval approved before 1982

    Publications:

  • TdgClinicalTrial: IMIPRAMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antidepressive Agents, Tricyclic
    Drug Class small molecule
    FDA Approval Approved before 1982

    Publications:

  • NCI: IMIPRAMINE

    • Version: 14-September-2017

    Alternate Names:
    C29116 NCI drug code

    Drug Info:

    Publications:
    Yagasaki et al., 2006, Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release., J. Biol. Chem.
    Kitamura et al., 2002, Effects of imipramine and lithium on wet-dog shakes mediated by the 5-HT2A receptor in ACTH-treated rats., Pharmacol. Biochem. Behav.

  • DTC: IMIPRAMINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL11 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: imipramine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

  • TTD: Imipramine

    • Version: 2020.06.01

    Alternate Names:
    D06ZUK TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL11

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Imipramine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21